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Abstract 
Targeted tissue drug delivery is a challenge in contemporary nanotechnologically driven therapeutic 
approaches, with the interplay interactions between nanohost and encapsulated drug shaping the 
ultimate properties of transport, release and efficacy of the drug at its destination. Prompted by the 
need to pursue the synthesis of such hybrid systems, a family of modified magnetic core-shell 
mesoporous silica nano-formulations was synthesized with encapsulated quercetin, a natural 
flavonoid with proven bioactivity. The new nanocarriers were produced via the sol-gel process, using 
tetraethoxysilane as a precursor and bearing a magnetic core of surface-modified monodispersed 
magnetite colloidal superparamagnetic nanoparticles, subsequently surface-modified with 
polyethylene glycol 3000 (PEG3k). The arising nano-formulations were evaluated for their textural 
and structural properties, exhibiting enhanced solubility and stability in physiological media, as 
evidenced by the loading capacity, entrapment efficiency results and in vitro release studies of their 
load. Guided by the increased bioavailability of quercetin in its encapsulated form, further 
evaluation of the biological activity of the magnetic as well as non-magnetic core-shell nanoparticles, 
pertaining to their anti-amyloid and antioxidant potential, revealed interference with the 
aggregation of β-amyloid peptide (Aβ) in Alzheimer’s disease, reduction of Aβ cellular toxicity and 
minimization of Aβ-induced Reactive Oxygen Species (ROS) generation. The data indicate that the 
biological properties of released quercetin are maintained in the presence of the host nanocarriers. 
Collectively, the findings suggest that the emerging hybrid nano-formulations can function as 
efficient nanocarriers of hydrophobic natural flavonoids in the development of multifunctional 
nanomaterials toward therapeutic applications. 
  
Introduction 
Applications of nanotechnology in biomedicine and pharmaceutics have provided an opportunity to 
address and treat challenging diseases by exploiting processes of drug encapsulation, biomolecular 
conjugation, and surface functionalization in the development of nanoparticle-based drug 
formulations [1]. Through manipulation of size and surface characteristics as well as diversity of 
starting materials used, emerging nanoparticles (NPs) can be developed into ‟smart vehicles”, 
encasing therapeutic and imaging agents to improve their pharmacokinetic profile and 
bioavailability, thus facilitating targeted delivery and controlled release at the desired tissue, with 
minimum side effects [2]. Until today, several types of NPs have been used in biomedical 
applications as drug delivery systems [3–6], involving polymeric micelles, liposomes, dendrimers, 
block ionomer complexes, polymeric and inorganic particles, quantum rods and nanorods [7]. 
Compared to simple structure NPs, however, core-shell-structured NPs, exhibit a more diverse 
functional profile, mainly due to their unique structural characteristics and physicochemical 
properties, including reduced cytotoxicity, enhanced dispersibility, biocompatibility, increased 
chemical and thermal stability, and improved conjugation or surface modification with bioactive 
molecules [8].  
One class of inorganic NPs with distinct advantages in drug delivery applications is mesoporous silica 
NPs (MSNPs) [9–11]. MSNPs possess a remarkably large surface area, well-defined pore 
arrangement with tunable pore sizes, adjustable design for the accommodation of drugs, imaging 
agents or both, and ease of inner and outer surface functionalization. These properties improve drug 
immobilization, stability in suspension, and sustained drug release [12]. MSNPs are chemically and 
thermally stable, however, their matrix undergoes biodegradation through hydrolysis. Degradation 
of MSNPs produces beneficial monomeric silicic acid [13], thus rendering MSNPs more appealing 
compared to other non-biodegradable species of inorganic NPs. 
 Magnetic targeting has been widely applied to direct MSNPs toward specific cellular targets and 
disease tissue locations [14]. This is commonly achieved through encapsulation of biocompatible 
superparamagnetic iron oxide (SPIO) NPs of proper surface architecture [15–19]. Key features of 
SPIOs include their ability to a) exhibit magnetization only in an applied magnetic field, b) form 
stable colloidal suspensions, especially in vivo, and c) direct themselves toward a specific site in the 
body by a magnetic force, thereby turning useful in controlled targeted drug delivery applications 
clinically. Furthermore, SPIO NPs possess uniform shape, controllable size distribution, strong 
magnetic susceptibility, and large surface area, which can be functionalized with specific 
biomolecules [20–22]. Research reports have proven that encapsulation of SPIO NPs in a 
mesoporous silica matrix enhances the chemical stability of magnetic NPs (MNPs) and reduces their 
potential cytotoxicity [23].  
On the basis of the aforementioned, we herein report on the formation of core-shell magnetic 
mesoporous silica NPs (MMSNPs) as nanocarriers of the flavonoid quercetin (QC). QC (Fig. 1A) has 
received considerable attention due to its high radical scavenging activity and antioxidant potential 
[24–27]. Furthermore, QC plays an important neuroprotective role against agent-induced toxicity 
[28], and increases the resistance of neurons to excitotoxicity and oxidative stress by modulating 
mechanisms of cell death [29,30]. QC has been shown to protect primary neurons against the Аβ 
amyloid peptide in Alzheimer’s disease, a property attributed to its antioxidant potential against the 
Aβ- induced oxidative stress [31] and also to its efficacy in preventing aggregation of Аβ into toxic 
assemblies (oligomers, protofibrils, amyloid fibrils) in vitro [32]. Its poor aqueous solubility and 
bioavailability, however, limits its therapeutic efficacy in clinical trials. As a result, several types of 
nano-formulations have been presented for the efficient encapsulation of QC in an effort to 
overcome limitations arisen through its low bioavailability [33–41]. 
Aiming at the development of new multifunctional pharmaceutical nano-formulations involving 
antioxidant flavonoids, QC was encapsulated for the first time in modified magnetic core-shell 
MMSNPs. The anti-amyloidogenic and antioxidant activity of QC released from the MMSNPs was 
evaluated with biophysical studies involving circular dichroism (CD), thioflavin T fluorescence assay, 
and transmission electron microscopy, as well as biological assays in primary neuronal cell cultures. 
More specifically, a) the synthesis of polyethylene glycol 3000 (PEG3k) surface-modified 
monodispersed magnetite colloidal MNPs (Fe3O4-PEG3k NPs) was pursued, b) core-shell MMSNPs 
(mentioned henceforth as empty MMSNPs, EMMSNPs) were developed via the sol-gel method, c) 
the suitability of the arising core-shell MMSNPs, as potential nanocarriers of QC (mentioned 
henceforth as QC-loaded MMSNPs, QCMMSNPs), was evaluated, d) the structural and textural 
properties of the encapsulated material were investigated through 
 
Fig. 1. A) Schematic representation of QC, B) Schematic illustration of a core-shell QCMMSNP, C) QC 
dispersed in PBS (left), QCMMSNPs dispersed in PBS (right). Encapsulation of QC in MMSNPs 
enhances its aqueous solubility 
2. Experimental section  
2.1. Materials  
The starting materials used include: Iron(II) chloride tetrahydrate (FeCl2•4H2O), iron(III) chloride 
hexahydrate (FeCl3•6H2O), ammonia solution (~25%), polyethylene glycol 3000 monodisperse 
solution (PEG3k) (~50% in H2O), quercetin (QC), tetraethyl orthosilicate (TEOS), and phosphate 
buffered saline (PBS) pH 7.4. All of the aforementioned materials were purchased from commercial 
sources (Sigma, Fluka) and were used without further purification. Ultrapure water (H2O), methanol 
(MeOH), ethanol (EtOH) and dimethyl sulfoxide (DMSO) were used as solvents. Nitrogen gas was 
used for degassing ultrapure H2O and establishment of nitrogen atmosphere during synthesis, 
where applicable. Amyloid peptide, Aβ40, was purchased from Anaspec (USA, >95% pure). The 
media/agents for the cultures of primary neuronal cells were purchased from Thermo Fisher 
Scientific (USA). The MTT reagent (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) 
was purchased from Applichem (Germany; >98% pure), while 2′ ,7′ -dichlorofluorescin diacetate 
(DCFH-DA) and thioflavin T (ThT) from Sigma-Aldrich (USA; >97% pure).  
2.2. Characterization  
FT-Infrared spectra were recorded on a Perkin Elmer 1760× FT-infrared spectrometer.  
XRD data on Fe3O4-PEG3k NP, EMMSNP and QCMMSNP samples were acquired using a Bruker D8 
Advance Eco diffractometer with Cu Kα radiation. Data were acquired with a 192-channel position 
sensitive detector at 0.01o intervals, using fixed divergence and detector slits, 2.5◦ anti-scatter Soller 
slits, and a Ni Kβ filter in the incident beam path. The samples were prepared for analysis by gentle 
grinding to a fine powder using a clean agate pestle and mortar. Subsamples were dispersed onto 
offset low-diffraction silicon sample mounts to generate uniform layers of approximately 0.5 mm in 
thickness.  
Magnetization measurements on Fe3O4-PEG3k NP, EMMSNP and QCMMSNP dried powder samples 
were performed on a QD-Versalab Vibrating Sample Magnetometer (VSM), in fields up to 3 T and 
temperatures from 50 K to 400 K.  
Transmission electron microscopy (TEM) images of Fe3O4 NPs, was acquired using a JEOL JEM-2100 
Transmission Electron Microscope operated at 80 kV. 8 μL of the sample (PBS dispersion) was 
deposited onto a formvar/carbon coated grid for 2 min and subsequently stained with 2% wt•vol􀀀 1 
uranyl acetate for 2 min. The sample was air-dried before TEM analysis. TEM images of Fe3O4-PEG3k 
NPs, EMMSNPs and QCMMSNPs were acquired using a FEI CM20 TEM, with particle size analysis 
performed manually through ImageJ software. Samples for TEM analysis were prepared by 
sonicating each one separately in heptane, and pipetting a portion of the resulting mixture onto a 
holey carbon support film on 300 mesh copper grid. The system was allowed to dry in air, leaving a 
small amount of each sample on the grid, ready for analysis. Images were obtained on a range of 
magnifications, using an accelerating voltage of 200 kV.  
The morphology and detailed structural features of Fe3O4-PEG3k NPs, EMMSNPs and QCMMSNPs 
were investigated by scanning electron microscopy (SEM), using a high-resolution microscope FEI 
Quanta 3D FEG model, equipped with an energy dispersive X-ray (EDX) spectrometer Apollo X. 
Analyses were performed in high vacuum mode, at different accelerating voltages (5–20 kV), with 
the pellets being analyzed directly (samples were immobilized on a double-sided carbon tape, 
without coating).  
Additional morphological and structural characteristics of the QCMMSNP samples were obtained via 
field emission scanning electron microscopy (FESEM), using a JSM-7000F microscope. A 10 μL sample 
(PBS dispersion, diluted 1:10) was deposited on a circular cover glass (immobilized on a double-sided 
carbon tape) and was air dried overnight. Samples were additionally covered with 10 nm Au/Pd 
sputtering. Data analyses were performed in high vacuum mode, in a 15 kV accelerating voltage.  
XPS spectra of Fe3O4-PEG3k NPs, EMMSNPs and QCMMSNPs samples were acquired using a 
bespoke ultra-high vacuum system, fitted with a Specs GmbH Focus 500 monochromated Al Kα X-ray 
source and Specs GmbH Phoibos 150 mm mean radius hemispherical analyser with 9-channeltron 
detection. Survey spectra were acquired over the binding energy range 0–1100 eV, using a pass 
energy of 50 eV. High resolution scans over the C 1s, O 1s and Fe 2p photoelectron lines were made 
using a pass energy of 20 eV. Data were quantified using Scofield cross-sections, corrected for 
energy dependencies of the effective electron attenuation lengths and analyser transmission. Data 
processing and curve fitting were carried out using CasaXPS software v2.3.16. The samples were 
prepared for analysis by gentle grinding to a fine powder using a clean agate pestle and mortar.  
Mean hydrodynamic diameter determination was pursued through Dynamic Light Scattering (DLS), 
using Photon Correlation Spectroscopy (Malvern S4700 PCS System, Malvern Instruments Ltd., 
Malvern, UK). Analysis was performed at a scattering angle of 90◦ and at 25 ◦C, using samples 
appropriately dispersed in PBS (pH 7.4). For each sample, the mean diameter ± standard deviation 
(±SD) of six determinations was calculated, applying multimodal analysis. Values reported are the 
mean diameter ± SD for three replicate samples.  
Zeta-potential measurements on Fe3O4-PEG3k NP, EMMSNP and QCMMSNP samples were obtained 
through Laser Doppler Anemometry (Malvern Zetasizer IV, Malvern Instruments Ltd., Malvern, UK). 
All analyses were performed on samples, appropriately diluted with PBS buffer (pH 7.4), in order to 
maintain constant ionic strength. The refractive index and viscosity of the medium were set at 1.335 
and 1.0200 [42], respectively. For each sample, the mean value standard deviation of four 
determinations was established. Values reported are the mean value SD of two replicate samples.  
Discovery TGA 550 from TA Instruments was used to run the simultaneous Thermogravimetric 
Analysis (TGA) experiments. The instrument mass weighing resolution is 0.1 μg. A specific amount 
(mg) of each sample was placed in an open platinum sample pan for analysis. High purity air was 
used at a constant flow rate of 25 mL•min􀀀 1. During TGA analysis, the sample weight loss and rate 
of weight loss were recorded continuously under dynamic conditions, as a function of time or 
temperature, in the range from room temperature to 800 ◦C. Prior to activating the heating routine 
program, the entire system was purged with the appropriate gas for 10 min, at a rate of 25 mL•min-
1, to ensure that the desired environment had been established.  
A Tristar 3000 Gas Adsorption Analyser and a VacPrep 061 Degasser by Micromeritics were used for 
the determination of the Brunauer- Emmett-Teller (BET) and Barrett-Joyner-Halenda (BJH) surface 
area, pore size and pore volume of the NPs via N2 gas sorption. The samples were properly weighed 
and degassed before installing them on the sample ports for analysis. About 150 mg of each sample 
was weighed on a balance and transferred to the sample tubes for degassing. Degassing was 
pursued by applying vacuum at room temperature for at least 48 h. After completion of sample 
degassing, analysis ensued.  
Determination of entrapment efficiency and the in vitro release study of QC were performed 
through UV–Visible (UV–Vis) measurements on a Hitachi U-2001 spectrophotometer.  
All measurements were performed immediately following NP preparation. 
2.3. Synthesis of Fe3O4-PEG3k NPs 
Quantities of 2.7 g (0.010 mol) of FeCl3⋅6H2O and 1.0 g (5.0 mmol) of FeCl2•4H2O were dissolved 
separately in two closed vessels in 20 mL of degassed ultrapure H2O, pretreated with inert nitrogen 
gas bubbling for 30 min, and then mixed in a three-neck flask under a nitrogen atmosphere. The 
resulting solution was vigorously stirred at 80 ◦C for 60 min. Subsequently, 6 mL of ammonia solution 
was added drop by drop until pH 10.5. The resulting mixture was allowed to stir for 30 min at 80 ◦C 
and then cooled to room temperature. A black precipitate was obtained from the reaction mixture 
via magnetic separation by means of a permanent magnet and the supernatant was removed by 
decantation. The resulting Fe3O4 NPs were washed three times with ultrapure H2O and 
resuspended in 20 mL of degassed ultrapure H2O in a three-neck flask under a nitrogen atmosphere. 
To that, 10 mL of PEG3k solution was added under vigorous stirring and the resulting mixture was 
further stirred for 60 min at 50 ◦C. Subsequently, ammonia solution was added until pH 7.5 under 
continuous stirring and the mixture was allowed to stir for an additional 2 h at 50 ◦C. A dark brown 
precipitate was collected by centrifugation at 6000 rpm for 30 min at 25 ◦C. The resulting Fe3O4- 
PEG3k NPs were washed three times, with ultrapure H2O, to remove unreacted PEG, recentrifuged 
and resuspended in 20 mL of degassed ultrapure H2O in a closed dark vessel, and stored at 4 ◦C for 
further use. Unmodified Fe3O4 NPs, without PEG3k stabilization, were prepared for comparative 
purposes in the ensuing physicochemical characterization and biological experiments, following a 
similar procedure with no addition of PEG3k. 
2.4. Synthesis of QCMMSNPs 
A quantity of 0.25 g of dried Fe3O4-PEG3k NPs at 50 ◦C for 24 h was suspended in 20 mL of degassed 
ultrapure H2O in a three-neck flask under a nitrogen atmosphere. Subsequently, ammonia solution 
was added until pH 8.0 under continuous stirring and the mixture was allowed to stir for an 
additional 10 min at 50 ◦C. Then, 0.25 g of QC and 40 mL of ethanol were mixed at 50 ◦C, under 
continuous stirring, and added to the suspension. The resulting mixture was further stirred 
vigorously for 80 min at 50 ◦C. To the mixture, 7 mL of TEOS was dripped in, and the resulting 
solution was vigorously stirred for 18 h at 50 ◦C. On the following day, a dark brown-green 
precipitate was obtained after centrifugation of the reaction mixture at 6000 rpm for 30 min at 25 
◦C, rinsed three times with ultrapure water to remove non-encapsulated QC, recentrifuged, and 
stored at 4 ◦C in a closed dark vessel for further use. EMMSNPs were synthesized following the same 
procedure with no addition of QC. 
2.5. Synthesis of EMSNPs and QCMSNPs 
EMSNPs and QCMSNPs, with 0.25 g of QC, as the initial amount of flavonoid employed in the 
encapsulation procedure, were synthesized according to previously reported work [37]. They were 
used for comparative purposes in the ensuing biological experiments. 
2.6. Determination of QC entrapment efficiency and loading capacity 
The percentage of encapsulated QC into QCMMSNPs was estimated by UV–Visible 
spectrophotometry at the characteristic wavelength of QC absorption (370 nm) [43]. A quantity of 
0.10 g of QCMMSNP powder was ground and immersed into 30 mL of MeOH-DMSO solution (MeOH: 
DMSO, 5:1 v/v). The resulting QCMMSNP dispersion was sonicated for 20 min and vortexed for 10 
min, in order to ensure complete release of the encapsulated QC. The resulting empty precipitated 
MMSNPs were removed by centrifugation at 6000 rpm for 25 min at 25 ◦C. An aliquot of 3 mL was 
withdrawn with a pipette and the absorbance of the supernatant clear solution was measured 
following appropriate dilutions. The concentration of QC was determined using the following 
calibration curve of QC concentrations in MeOH-DMSO solution vs. absorbance values: A = 77.32C + 
0.025 (R2 = 0.997), where A is the absorbance at 370 nm and C is the concentration of QC (mg•mL-1). 
The entrapment efficiency and loading capacity of QC were calculated using the following equations:  
Entrapment Efficiency (%) = QCi/QCt × 100, where QCi is the amount (mg) of QC incorporated into 
MSNPs and QCt is the initially added amount of QC, respectively.  
Loading Capacity (%) = QCi/WQCMMSNPs × 100, where QCi is the amount of QC (mg) incorporated 
into QCMMSNPs and WQCMMSNPs is the weight of the synthesized QCMMSNPs after drying. 
Experiments were carried out in triplicates and the results were expressed as mean ± SD. 
2.7. In vitro QC release study 
The QC release profile of QCMMSNPs was obtained as follows: 0.10 g of QCMMSNP powder was 
ground and immersed into 30 mL of PBS (pH 7.4), under continuous stirring at a rate of ca. 400 rpm, 
at 37 ± 1 ◦C. Aliquots of 3 mL were withdrawn with a syringe, at fixed time intervals, for analysis and 
centrifuged at 6000 rpm for 1 min, to remove the insoluble QCMMSNP residue. The amount of QC 
released was determined by UV–Vis spectrophotometry in the clear solution at 370 nm via the 
aforementioned calibration curve (vide supra). Experiments were carried out in triplicates and the 
results were expressed as mean ± SD. 
2.8. Preparation of Aβ and NP samples 
Aβ40 was gently dissolved without vortexing in Type 1 (Milli-Q) water to a final concentration of 100 
μM. Solutions of plain Aβ40 in phosphate buffer (PB, 10 mM, pH 7.33) were prepared by adding PB 
to aliquots of the 100 μМ stock to achieve final concentration of 50 μM. In the preparation of the 
Aβ/NP mixtures, the ratios 1:0.5 and 1:1 were calculated based on the amount of QC released from 
each kind of NP, as projected into their respective release curves (Section 3.12) [37]. Based on the 
curve, the proper amount (mg) of NPs was weighed in order to prepare a 100 μM solution of 
released QC in PB. To prepare the Aβ:NP 1:1 ratio, equal volumes of the 100 μМ Аβ stock and the 
100 μM QC solution were mixed. For the Aβ:NP 1:0.5 ratio, a dilution in half of the 100 μM QC 
solution with PB was necessary. Verification of the amount of QC present in solution was made 
through UV–Vis measurements (Section 3.13) of the samples. 
2.9. Circular dichroism studies 
Appropriate amounts of well-dried NPs were weighed and added to 50 μМ Aβ40 solutions to give 
the desired Aβ:NP molar ratios of 1:0.5 and 1:1. Aβ structural changes were monitored for 
approximately 30 days at 33 ◦C under quiescent conditions. CD spectra were recorded on a JASCO J-
715 spectropolarimeter (Jasco Co., Japan) in the range of 190–260 nm, with a 1 mm path length 
quartz cuvette. Each spectrum was the average of three scans at a rate of 100 nm⋅min􀀀 1 and a 
resolution of 0.5 nm. Three independent experiments were performed for each condition and in 
each case solutions of plain Aβ, NPs and QC were run as controls. Analysis of the CD data was 
performed using the OriginPro 9 program. In the absence of Aβ, the NPs, being investigated, exhibit 
weak CD signals that do not change with time (Fig. S3, Supplementary Information). 
2.10. Thioflavin T assay 
For the ThT assay, 100 μL of the aged (30 days) CD solutions of Aβ40 (with or without the NPs) was 
diluted to half with PB (10 mM, pН 7.33), to obtain 200 μL of final solutions with theoretical Aβ40 
concentration of 25 μM. To these solutions, a stock solution of ThT in PBS (10 mM, pН 7.33) was 
added to achieve a final concentration of ThT of 5 μM. The mixture was well-agitated by pipetting 
and immediately thereafter fluorescence was monitored following excitation at 440 nm (emission 
slit = 2.5 nm, PMT Voltage 700 V, response 0.4 s) with a HITACHI F- 2500 spectrofluorimeter. The 
analysis of fluorescence data was performed using the OriginPro 9 program. 
2.11. Cell cultures 
Hippocampal neuronal cultures were obtained from postnatal mice (<2 day old). Briefly, after being 
dissected, the hippocampus was incubated with 0.25% trypsin for 15 min at 37 ◦C. The hippocampi 
were then rinsed in 10 ml of Hibernate, containing 10% (v/v) heat-inactivated fetal bovine serum 
(FBS). Cultures were maintained in Neurobasal-A medium containing 2% B-27 supplement, 0.5 mM 
Gluta-MAX and 1% penicillin/streptomycin at 37 ◦C and 5% CO2. Half of the medium was replaced 
twice a week. For MTT cytotoxicity and Reactive Oxygen Species (ROS) intracellular studies, neuronal 
hippocampal cells were plated at a density of approximately 2 × 104 per well in 96-well plates and 
incubated at 37 ◦C for 24 h to allow cells to attach, followed by seven additional days of incubation 
to allow cells to differentiate. For all measurements, cells were subsequently treated with the 
indicated concentrations of Aβ in the presence or absence of NPs, as described in the next 
paragraph. 
2.12. Cell viability evaluation 
Solutions of Aβ40 (10 μM) in PBS, in the absence or presence of NPs (1:1 and 1:2 ratio of Aβ:NPs, 
based on the released QC (Section 3.13)), pre-incubated at 37 ◦C, were diluted with fresh medium 
and added to individual wells at a final concentration of Aβ40 of 1 μM. According to our previous 
studies [44], pre-incubation of Aβ40 for 3 d was necessary in order for Aβ40 to exert maximum 
neurotoxicity. After a 24 h exposure of cells to the Aβ40 solutions, 100 μL of a 0.5 mg•mL􀀀 1 stock 
solution of MTT in Neurobasal-A was added to each well of primary hippocampal neurons, followed 
by a 3 h incubation at 37 ◦C. The medium was removed and the cells were diluted in DMSO. The 
relative formazan concentration was measured by determination of the absorbance at 540 nm 
(Tecan well plate reader). Results were expressed as percentage of MTT reduction, assuming that 
the absorbance of control (untreated) cells was 100%. Data are presented as the mean of three 
independent experiments with six replicate wells for each condition. Graphs were analyzed using 
GraphPad Prism 5.0 software. In each run, the effect of solutions of plain Аβ and NPs was 
independently checked to serve as internal standard. 
2.13. Intracellular ROS measurements 
Primary hippocampal neurons were treated with Аβ40 and NP solutions as previously described in 
Section 2.12. After incubation for 24 h, cells were washed with PBS and incubated with 10 μM of 
DCFH-DA for 30 min at 37 ◦C in the incubator with 5% CO2. The fluorescence intensity of DCF, 
representing ROS levels, was determined using a Tecan fluorescence well plate reader, at the 
excitation wavelength of 485 nm and emission wavelength of 528 nm. Control groups consisted of 
cells incubated with medium only and plain Aβ or NPs. 
2.14. Statistical analysis 
Data in all assays are the mean of at least three independent experiments. The statistical significance 
of changes in different groups was evaluated by one-way analysis of variance (ANOVA) and Student 
t-tests, using GraphPad Prism 5.0 software. For each experiment, data are expressed as the mean ± 
standard error of the mean (SEM, n = 3), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ns (not significant) > 
0.05. 
  
3. Results and discussion 
3.1. Synthesis 
modified Massart method was used for the synthesis of Fe3O4 NPs, which were employed as the 
main core of the nanocarriers. More specifically, ferric chloride and ferrous chloride in a 2:1 molar 
ratio were co-precipitated upon addition of excess ammonia solution [45,46]. The surface of the 
obtained Fe3O4 NPs was negatively charged through surface functionalization with PEG3k, in order 
to generate a ferromagnetic suspension of colloidal, structurally stabilized, Fe3O4 NPs, surface-
modified with long polymeric PEG chains (Scheme 1). In general, surface functionalization of 
superparamagnetic magnetite NPs with biocompatible polymeric moieties, such as PEG, reduces 
their cytotoxicity, improves their colloidal stability in physiological media by preventing 
agglomeration, and enhances their blood circulation half-life (Scheme 1) [47]. Both procedures, co-
precipitation and surface modification with PEG3k, were carried out under anaerobic conditions and 
vigorous stirring at constant temperature, 80 ◦C, and 50 ◦C, respectively, to ensure reagent 
homogeneity, and in the liquid phase to prevent surface passivation of the produced NPs. The high 
pH (pH 10.5), maintained during the Fe3O4 NP synthetic procedure, prevented surface charge-
induced agglomeration, since the isoelectric point of Fe3O4 depends highly on pH (6.25 ≤ pH ≤ 7.10) 
[48–51], temperature, and Fe(II) concentration [52,53]. During surface modification with PEG3k, the 
pH of the reaction was 7.5, in order to ensure: i) negative particle surface charge of the resulting 
PEGylated MNPs [54], ii) stabilization of the NP size by both electrostatic and steric repulsion 
between PEG chains on the surface of the particles [55], and iii) enhanced NP stability in aqueous 
media, at pH in the near-physiological pH range [56]. Core-shell QCMMSNPs (Fig. 1B) were prepared 
following initial incorporation of an ethanolic solution of QC to an aqueous dispersion of Fe3O4-
PEG3k NPs and subsequent formation of SiO2 nanocarriers via sol-gel reaction upon addition of 
tetraethoxysilane (TEOS) to the emerging flavonoid- MNPs mixture. Ammonia was employed as the 
catalyst of TEOS hydrolysis, in order to achieve better control of size and morphology of the resulting 
silica powders [57]. The employed sol–gel process describes the transition of a system from a sol, a 
liquid with relatively low viscosity, into a solid gel phase through condensation and cross-linking of 
the emerging colloidal particles, resulting in an intense enhancement of viscosity [58]. A silicon 
alkoxide, such as TEOS, is used as the precursor for the sol–gel reaction. At first, a hydrolysis reaction 
of the alkoxide takes place, which is catalyzed by a base or an acid (Scheme 2). Hydrolysis products 
include hydrated silica tetrahedra that interact further via a condensation reaction to give rise to 
intermediate moieties linked through a siloxane bond [Si-O-Si] (Scheme 2). Further polycondensation 
leads to formation of a silica network (Scheme 2) through linkage of additional silanols. The 
condensation products are water and alcohol, which remain in the pores of the silica network [58]. 
The effective encapsulation of QC into the MMSNPs aims at improving its aqueous solubility, 
circulation time, systemic bioavailability, targeted delivery, controlled release, thus contributing to 
enhanced therapeutic potential. Indeed, as can be seen in Fig. 1C, encapsulation of QC efficiently 
enhances its solubility in aqueous media (PBS). 
3.2. FT-IR spectroscopy 
The FT-IR spectra of Fe3O4 NPs, PEG3k, and Fe3O4-PEG3k NPs are presented in Fig. 2A. More 
specifically, the spectrum of unmodified Fe3O4 NPs shows two characteristic absorption bands 
attributed to the Fe 􀀀 O vibrations, a weak shoulder at 620 cm􀀀 1 and a sharp band at 537 cm􀀀 1 
[59]. Similar absorption bands have been observed in the spectrum of Fe3O4-PEG3k NPs at 623 cm􀀀 
1 and at 548 cm􀀀 1 [60]. In the spectrum of PEG3k, the broad absorption band observed at around 
3448 cm􀀀 1 can be attributed to the O 􀀀 H stretching vibrations, whereas the sharp absorption bands 
at 2916 cm􀀀 1 and 1103 cm􀀀 1 can be assigned to the C 􀀀 H and C 􀀀 O stretching vibrations, 
respectively [48]. Similar absorption bands have been observed in the spectrum of Fe3O4-PEG3k NPs 
at 3430 cm􀀀 1 for the O 􀀀 H stretching vibrations, 2988 cm􀀀 1 for the C 􀀀 H stretching vibrations, and 
1066 cm􀀀 1 for the C 􀀀 O stretching vibrations, respectively. The above results indicate successful 
surface modification of Fe3O4 NPs with PEG3k. 
The FT-IR spectra of EMMSNPs, QC, and QCMMSNPs are presented in Fig. 2B. More specifically, in 
the spectrum of EMMSNPs, characteristic absorption bands assigned to the Fe 􀀀 O vibrations are 
observed at 621 cm􀀀 1 and 556 cm􀀀 1. The very broad absorption band at around 3359 cm􀀀 1, the 
broad plateau observed at around 2955 cm􀀀 1, and the sharp absorption band at 1070 cm􀀀 1 can be 
attributed to the O 􀀀 H, C 􀀀 H, and C 􀀀 O stretching vibrations, respectively, of the PEG3k moieties on 
the surface of the encapsulated Fe3O4-PEG3k NPs. The Si–O–Si symmetric stretching and bending 
vibrations appear at 766 cm􀀀 1 and 479 cm􀀀 1, respectively, with Si–O–Si antisymmetric stretching 
vibrations appearing at 961 cm􀀀 1 [61,62]. In the spectrum of QCMMSNPs, the absorption bands 
attributed to the O 􀀀 H, C 􀀀 H, and C 􀀀 O stretching vibrations of the PEG3k moieties of the 
encapsulated PEGylated MNPs are observed at 3204 cm􀀀 1, 2876 cm􀀀 1, and 1061 cm􀀀 1, 
respectively. The Fe 􀀀 O vibrations are observed at 620 cm􀀀 1 and 550 cm􀀀 1. The Si–O–Si symmetric 
stretching and bending vibrations are observed at 798 cm􀀀 1 and 470 cm􀀀 1, respectively, with Si–
O–Si antisymmetric stretching vibrations appearing at 948 cm􀀀 1. The characteristic carbonyl (–C=O) 
and aromatic stretching vibrations of QC are observed at 1652 cm􀀀 1 and 1598 cm􀀀 1, respectively, 
with phenolic O–H bending vibrations observed around 1319 cm􀀀 1 and 1350 cm􀀀 1 [63,64]. The 
obtained results confirm a successful encapsulation of QC in the MMSNPs. 
 
Scheme 1. a) Chemical reactivity showing the synthesis of Fe3O4 NPs, and b) Schematic illustration 
of NP further functionalization to a colloidal suspension of Fe3O4-PEG3k NPs. 
3.3. X-ray diffraction 
Data from 9◦ to 95◦ for the Fe3O4-PEG3k NP, EMMSNP, and QCMMSNP samples are shown in Fig. 3. 
The three traces are offset vertically for clarity. The main diffraction peaks for Fe3O4 (magnetite), 
with their Miller indices, are labelled using reference data from the JCPDS PDF database card 
reference 01–086-1339 (star quality). In the case of the QCMMSNP sample, additional low intensity 
peaks were detected in the lower angle range and are matched with reference data for QC (PDF 
reference 00–043-1695). The broad hump in the data peaking at approximately 21◦–22◦, seen for 
EMMSNP and QCMMSNP samples, is attributed to amorphous silica. The background intensity, 
particularly noticeable in the case of the Fe3O4-PEG3k NP sample, is due to fluorescence from the 
Fe-containing sample material. The origin of the broad structure in the range ~ 10◦–15◦ is unknown. 
However, it corresponds to spacings in the range of ~0.3–0.44 nm, indicating a weaker structure on 
this scale. Low angle data (2ο < 2θ < 10ο) on QCMMSNP samples suggest no ordered pore structure. 
 
Fig. 2. FT-IR spectra of A) Fe3O4 NPs, PEG3k, and Fe3O4-PEG3k NPs, and B) EMMSNPs, QC, and 
QCMMSNPs 
 
Fig. 3. XRD data from Fe3O4-PEG3k NP, EMMSNP, and QCMMSNP samples, offset vertically for 
clarity and with principal diffraction peaks labelled. 
3.4. XPS measurements 
3.4.1. XPS composition analysis 
XPS analysis of the Fe3O4-PEG3k NP samples showed the presence of only Fe, O and C. In addition, 
Si was detected in EMMSNP and QCMMSNP samples. The survey spectra are shown in Fig. 4I, with 
the principal peaks labelled. The data were quantified to provide the surface composition shown in 
Table 1. It should be noted that the method of quantification a) provides an average composition in 
atom % over the information depth of the technique, assuming that composition does not vary 
within this depth, and b) is weighted toward the outermost surface layers. The information depth is 
in the range of ~5–10 nm, depending on sample composition and photoelectron energy. H and He 
are not detected by XPS. In the case of the Fe3O4-PEG3k NP sample, the ratio of Fe to O in Table 1 is 
not correct for Fe3O4. However, the sample is treated with PEG3k, which presumably coats the 
surface of the Fe3O4 NPs, in which case the Fe 2p signal would preferentially be attenuated by the 
carbon-containing overlayer relative to the O 1 s, thereby accounting for the apparent discrepancy. 
A similar argument applies to the apparent ratio of O to Si in the EMMSNP and QCMMSNP samples. 
3.4.2. XPS chemical state analysis 
Scans were run over individual photoelectron lines to provide additional information on the 
chemical states of the elements present (Figs. 4II–V). The Fe 2p spectrum for the Fe3O4-PEG3k NP 
sample consisted of a doublet due to the Fe 2p3/2 and 2p1/2 components, at approximately 710–
711 eV and 719–720 eV binding energy, respectively. Each of these components is accompanied by a 
shake-up peak, approximately 13 eV higher in binding energy. In the case of the Fe3O4- PEG3k NP 
sample, each main doublet component was fitted with two contributions to intensity, representing 
Fe(II) and Fe(III) in the Fe3O4 structure, which may be expressed as FeO•Fe2O3. The fitted 
components and constraints used during fitting are summarized in Table 2, confirming the Fe 
present as Fe3O4. This peak fitting model was applied to the Fe 2p XPS data from the EMMSNP and 
QCMMSNP samples and produced satisfactory fits, showing that the oxidations state of the Fe had 
not changed during subsequent treatments. However, it should be noted that the peak fitting for the 
EMMSNP sample and especially for the QCMMSNP sample was rather complex, mainly due to the 
rather poor signal to noise ratios, which can be attributed to the low levels of Fe present in these 
samples. 
The curve-fitted O 1s peaks are shown in Fig. 4III. The O 1s from the Fe3O4-PEG3k NP sample was 
fitted with three components at approximately 530.1 eV, 531.3 eV, and 532.8 eV. The component at 
532.8 eV is in very good agreement with reference data for PEG3k. The component at 530.1 eV is in 
good agreement with reference data for Fe3O4. It was not possible to obtain a satisfactory fit to the 
O 1s data from this sample, using just these two components. The additional component at 531.3 eV 
was attributed to the modification of the Fe3O4 surface states due to the presence of PEG3k. The O 
1s lines from the EMMSNP and QCMMSNP samples are dominated by strong components at 532.9–
533.1 eV, due to oxygen bonded to Si in the amorphous SiO2 phase. In both cases, weak 
contributions to intensity at approximately 530.3 eV can be seen, due to the low level of Fe3O4 
detected. At these levels, the possible Fe3O4/ PEG3k surface interaction component was not 
detected. 
The Si 2p peaks from the EMMSNP and QCMMSNP samples are shown in Fig. 4IV. In both cases, they 
are fitted by a single component at approximately 103.6 eV binding energy, consistent with Si in a 
SiO2 formulation. 
Curve-fitted C 1s spectra are shown in Fig. 4V. The spectrum from the Fe3O4-PEG3k NP sample 
showed a main component at 286.5 eV, in agreement with reference data for ester bonds as in 
PEG3k. In addition, a weak component at approximately 288.6 eV was detected. This is indicative of 
a carbon in a more polar oxygenated environment and may be associated with the 531.3 eV 
component in the O 1s spectrum of this sample and attributed to the Fe3O4/PEG3k interactions. The 
spectrum of the EMMSNP sample is similar to that of the Fe3O4-PEG3k NP sample, with an 
additional low-level component at a lower binding energy, typically associated with carbon in C–C 
hydrocarbon bonds. This may indicate a low level of additional material introduced with the SiO2 
NPs. The spectrum from the QCMMSNP sample showed a strong component at approximately 285.0 
eV, a relatively strong component at approximately 286.7 eV and a weaker component at 
approximately 289.2 eV. The 285.0 eV component is attributed to carbon atoms bonded to adjacent 
carbons in the QC molecular structure. The component at 286.7 eV is attributed to carbon singly-
bonded to oxygen in either the hydroxyl groups or the γ-pyrone fragment of QC, and also to the C-O-
C bonds in PEG3k. The weaker component at 289.2 eV may arise from the carbonyl bond in QC, but 
this also overlaps with the component at approximately 288.6 eV detected in the Fe3O4-PEG3k and 
EMMSNP samples, prepared without QC and attributed to the Fe3O4-PEG3k interactions. 
 
 
Fig. 4. I. XPS survey spectrum with principal photoelectron peaks labelled for A) Fe3O4-PEG3k NPs, B) EMMSNPs, and C) QCMMSNPs. II. Curve-fitted Fe 2p 
spectra for A) Fe3O4-PEG3k NPs, B) EMMSNPs, and C) QCMMSNPs. The fitted components, numbered 1 through 6, are as described in Table 2. III. Curve-
fitted O 1 s spectra for A) Fe3O4-PEG3k NPs, B) EMMSNPs, and C) QCMMSNPs. IV. Curve-fitted Si 2p spectra for A) EMMSNPs and B) QCMMSNPs. V. Curve 
fitted C 1 s spectra for A) Fe3O4-PEG3k NPs, B) EMMSNPs, and C) QCMMSNPs. 
 
3.5. TEM analysis 
TEM images of air-dried Fe3O4 NPs, FE3O4-PEG3k NPs, EMMSNPs, and QCMMSNPs are presented in 
Figs. 5A–G. TEM observations of Fe3O4 NPs (Fig. 5A) indicate their spherical morphology, with their 
average particle size being between 6 and 9 nm. TEM images of Fe3O4-PEG3k NPs (Figs. 5B and C 
and S2A, Supplementary Information) indicate the presence of predominantly spherical PEGylated 
magnetite NPs, with an average particle size between 20 and 30 nm and scattered small Fe3O4 
aggregates surrounded by a PEG3k layer. This aggregation could be attributed to the strong 
magnetic attraction between magnetite NPs, the repeated centrifugations during the synthetic 
procedure, the magnetic agitation during the stabilization with PEG3k, and the drying process before 
TEM measurements [66]. TEM images of the EMMSNP sample (Fig. 5D and E) project the presence of 
relatively globular core-shell magnetic silica nano-formulations around 120–140 nm with 
encapsulated distinct and agglomerated Fe3O4-PEG3k NPs formulating the magnetic core. In the 
case of the QCMMSNP sample (Fig. 5F and G), TEM observations suggest the presence of relatively 
agglomerated core-shell magnetic silica nanospheres, with sizes in the range 200–250 nm. The 
observed difference between the particle sizes of the empty and QC-loaded samples could be 
attributed to the presence of QC in the pores of the nanospheres that induces swelling of the silica 
matrix and thus an increase in the diameter of the produced QCMMSNPs. 
3.6. SEM and FESEM analysis 
The morphologies of all prepared samples were examined by SEM. Fig. 6 presents SEM images of the 
morphology of Fe3O4-PEG3k NPs (Fig. 6A), EMMSNPs (Fig. 6B), and QCMMSNPs (Fig. 6C), 
respectively. All samples display large and dense agglomerates of aggregated NPs, with an 
approximately uniform spherical morphology and a relatively narrow size distribution. In addition, 
FESEM examination of the QCMMSNP sample (Figs. S2B and S2C, Supplementary Information) 
further confirmed the presence of distinct core-shell nanospheres with sizes ranging between 200 
and 250 nm. 
 
Fig. 5. TEM images of A) Fe3O4 NPs at 0.2 μm, B) Fe3O4-PEG3k NPs at 50 nm, and C) 10 nm, D) 
EMMSNPs at 50 nm, and E) 20 nm, F) QCMMSNPs at 0.5 μm, and G) 100 nm. 
 
3.7. DLS and z-potential 
of appropriately diluted, with PBS buffer (pH 7.4), Fe3O4-PEG3k NP, EMMSNP and QCMMSNP 
samples, as presented in Figs. 7A–C. The results obtained indicate that the mean hydrodynamic 
diameter of Fe3O4- PEG3k NPs is around 81 nm, thus implying the existence of small agglomerates, 
which could emerge due to the high concentration of MNPs in the buffer solution. The singlet DLS 
peak is indicative of the high stability of the Fe3O4-PEG3k NP induced by the robust coating formed 
on the Fe3O4 surface by the PEG3k surface modification [47]. The mean hydrodynamic diameters of 
EMMSNPs and QCMMSNPs are around 261 nm and 282 nm, respectively, also implying the existence 
of scattered agglomerates in the buffered solution. The observed difference between the size of 
EMMSNPs and QCMMSNPs could be attributed to the QC load. 
The electrostatic interactions of all types of NPs are directly related to their surface charge, which 
was analyzed through zeta potential measurements. The PEG3k-surface modification of Fe3O4 NPs 
resulted in negatively surface-charged Fe3O4-PEG3k NPs (􀀀 10 ± 1 mV at pH 7.4), implying colloidal 
stability of the produced PEGylated Fe3O4 NPs in aqueous solution as a result of the electrostatic 
repulsion between the negatively charged NPs [47,65]. The surface charge of the EMMSNP and 
QCMMSNP samples, at pH 7.4, was measured to be 􀀀 33 ± 0.67 mV and -40 ± 1.19 mV, respectively. 
The observed very low zeta-potential values are indicative of enhanced stability and reduced 
sedimentation and aggregation rates of the corresponding NPs. Furthermore, the extended decrease 
of zeta-potential compared to that of Fe3O4-PEG3k NPs can be attributed to the large surface 
charge due to the deprotonation of the Si–OH groups [66,67]. In addition, the observed decrease of 
zeta-potential of QCMMSNPs compared to that of EMMSNPs can be attributed to the partial 
deprotonation of QC molecules at the pH of the medium [37,68]. 
The fact that, in the case of EMMSNPs, the hydrodynamic radius measured by DLS is approximately 
double the radius measured by TEM, whereas in the case of QCMMSNPs the measured radii with 
both methods are very close, could be attributed to the increased zeta-potential value of EMMSNPs 
compared to that of QCMMSNPs. The associated lower electrostatic repulsion between the 
EMMSNPs may result in greater agglomeration in solution, a fact that could explain the detection by 
DLS of larger hydrodynamic radii for EMMSNPs. 
3.8. BET analysis 
N2 sorption measurements were conducted to further determine the pore parameters of EMMSNPs 
and QCMMSNPs. All physicochemical properties of EMMSNPs and QCMMSNPs are summarized in 
Table 3, whereas the obtained N2 adsorption–desorption isotherms and pore size distributions are 
shown in Fig. 8A and B, respectively. Both samples show a typical type IV isotherm with H1 
hysteresis loop, indicative of the presence of mesoporosity [69–72]. The observed intense increase 
in N2 uptake in the relative pressure range between 0.70 and 0.90 for the EMMSNP sample and 
0.80–0.95 for the QCMMSNP sample could be attributed to the voids formed between SiO2 NPs 
[73]. The BJH pore sizes of EMMSNP and QCMMSNP samples were estimated to be 91.50 Å and 
168.96 Å, respectively. The BET average pore sizes of EMMSNP and QCMMSNP samples were found 
to be 150.64 Å and 273.12 Å, respectively. The BET surface areas and pore volumes were estimated 
to be 169.30 m2•g􀀀 1 and 0.64 cm3•g􀀀 1 for the EMMSNP sample, and 108.33 m2•g􀀀 1 and 0.74 
cm3•g􀀀 1 for the QCMMSNP sample, respectively. It can be concluded that the BET surface area 
decreases with the encapsulation of QC, whereas the BET average pore size and pore volume 




3.9. Thermal studies 
The thermal decomposition of Fe3O4-PEG3k NPs, EMMSNPs, and QCMMSNPs was studied by TGA 
under an atmosphere of air (Figs. 9A and B). The Fe3O4-PEG3k NP sample (Fig. 9A) was stable up to 
160 ◦C. The observed weight loss of about 10.5%, between 160 ◦C and 322 ◦C could be attributed to 
the decomposition of the chemisorbed PEG3k molecules. The negligible weight loss of about 0.6% 
between 322 ◦C and 573 ◦C could be assigned to the Fe3O4-Fe2O3 phase transformation [75]. No 
further weight loss was observed between 573 ◦C and 800 ◦C. The EMMSNP sample (Fig. 9B) was 
stable up to 34 ◦C. From that point on, a small weight loss of about 2.3% between 34 ◦C and 147 ◦C 
was observed, which could be assigned to the loss of the physisorbed water molecules. The 
observed weight loss of about 13.4% between 147 ◦C and 784 ◦C could be attributed to the 
decomposition of the chemisorbed PEG3k molecules and the condensation of silanols, which begins 
at temperatures above 350 ◦C [76]. The QCMMSNP sample (Fig. 9B) was stable up to 17 ◦C. From 
that point on, a small weight loss of about 3.6% was observed between 17 ◦C and 107 ◦C, which 
could be assigned to the loss of the physisorbed water molecules. The observed weight loss of about 
23.5%, between 107 ◦C and 766 ◦C could be attributed to the decomposition of the chemisorbed 
PEG3k and encapsulated QC molecules and the condensation of silanols. 
 
Fig. 8. Nitrogen adsorption-desorption isotherms of A) EMMSNPs, and B) QCMMSNPs. The inset 
images show the pore size distribution of each sample. 
 
Fig. 9. TGA diagrams of A) Fe3O4-PEG3k NPs, and B) EMMSNPs (black line), QCMMSNPs (red line). 
3.10. Magnetization measurements and determination of Fe3O4 content 
Fe3O4-PEG3k NP, EMMSNP and QCMMSNP samples exhibit a strong magnetic response when 
placed in a magnetic field. At room temperature, magnetization measurements in fields up to 3 T 
reveal a typical superparamagnetic character (Figs. 10A–C): the magnetic moments within a NP are 
magnetically coupled and behave as a single super moment. This ensemble aligns easily to any 
external magnetic field, thus providing high magnetization. In the absence of a magnetic field, the 
aligned moments of each NP (the “super moment”) fluctuate randomly as a whole due to thermal 
agitation, since the magnetic anisotropy energy barrier is lower than the thermal energy at room 
temperature, such that the sample has zero remanence and zero coercivity (inset of Figs. 10A–C). 
With decreasing temperature, below the superparamagnetic TB, the thermal energy is lower than 
the energy barrier and the magnetic moments are blocked when the magnetic field is zero or 
reversed, giving rise to remanence and coercivity. Indeed, coercivity is negligible at room 
temperature, 3–8 Oe (240–640 A⋅m-1), and the magnetization curve can be fitted to a paramagnetic 
Langevin function. For the QCMMSNP sample, at 50 K a switching field is required and a hysteresis 
loop has been developed (inset of Fig. 10D), with coercivity Hc ~ 120 Oe (9.6 kA⋅m-1). 
Superparamagnetic behavior is expected for the given size of the magnetic core, which is lower than 
the critical size Dsp, for superparamagnetism in iron oxide NPs (Dsp ~ 20–30 nm) [77]. 
The specific magnetization of the Fe3O4-PEG3k NP sample at the maximum field (3 T) at room 
temperature is 66.5 emu⋅g-1. From thermal analysis results (Section 3.9), the estimated content of 
Fe3O4 in the sample is 89.5%. Since the magnetic moments arise only from Fe3O4, the saturation 
magnetization of Fe3O4 core NPs is 66.5/89.5% = 74.3 emu⋅g-1. This value corresponds to 90% of the 
magnetization of bulk magnetite and the difference, in the case of NPs, is assigned to surface spin 
disorder that has a stronger influence with diminishing particle size, as previously explained [78]. The 
EMMSNP sample has a specific saturation magnetization σ = 7.285 emu⋅g-1. Taking into account the 
saturation magnetization of Fe3O4 core NPs estimated above (74.3 emu⋅g-1), Fe3O4 content 
corresponds to 7.285/74.3 = 9.8% w/w of this sample. Accordingly, in the QCMMSNP sample, the 
Fe3O4 content, estimated from the specific saturation magnetization of the sample, σ = 10.77 
emu⋅g-1, corresponds to 10.77/74.3 = 14.5% w/w of this sample. 
 
Fig. 10. Magnetization curves of A) Fe3O4-PEG3k NPs, B) EMMSNPs, C) QCMMSNPs at 300 K, and D) 
QCMMSNPs at 50 K. The magnetic field range in the inset graphs is 􀀀 1000 to +1000 Oe 
3.11. QC entrapment efficiency and loading capacity 
The in situ entrapment efficiency and loading capacity of QC in QCMMSNPs was estimated to be 
70.35% and 14.51%, respectively. The observed relatively high entrapment efficiency and loading 
capacity, despite the presence of the magnetic core, which occupies considerable volume of the 
interior of MMSNPs, are probably attributed to the high TEOS-to-QC molar ratio (≈37.9:1) employed 
in the synthesis of QCMMSNPs and the enhanced host/guest interactions due to intense hydrogen 
bond formation between the entrapped flavonoid, the silanol (Si-OH) groups and the PEG3k chains 
on the surface of the MNPs, thereby promoting a more efficient encapsulation of QC [79–81]. 
3.12. In vitro QC release study 
The release profile of the active encapsulated ingredient (QC), defined by the total amount of QC 
released and release rate, affects the modulation of the QCMMSNP pharmacokinetic behavior. Fig. 
11 shows the percentage of QC released with regard to the total entrapped QC versus time. The 
equilibrium release percentage of QC from QCMMSNPs, after 48 h of study, was estimated to be 
around 50.28%. Moreover, the release profile of the encapsulated QC showed that the release rate 
of the flavonoid was high up to the first 60 min and subsequently decreased significantly, becoming 
relatively steady after 6 h. This burst of QC release can be attributed to the large surface of the 
irregularly shaped silica xerogels, the relatively thin outer silica shell compared to the bulky magnetic 
core, the mesoporous structure of the produced QCMMSNPs, which allows facile penetration of the 
release medium, as well as the ionization of the silanol groups of the surface and the interior of the 
pores, which create an ionic environment non-compatible with the hydrophobic nature of QC 
[37,82]. 
 
Fig. 11. Cumulative release percentage of QC with regard to the total entrapped QC vs. time. 
3.13. Effect of NPs on Aβ aggregation 
The potential of the investigated NPs to inhibit aggregation of Aβ40 and formation of amyloid fibrils 
was studied through circular dichroism spectropolarimetry (CD). The typical aggregation process of 
Aβ40 produces characteristic CD spectra over time that reflect its transition from random coil 
(negative maximum at 198 nm) to β-sheet (positive maximum at 195 nm and negative maximum at 
218 nm) and the gradual formation of larger fibrillar aggregates that precipitate from solution, 
resulting in loss of the CD signal (Fig. 12A). In the presence of compounds that interact with Aβ and 
interfere with its aggregation, the typical spectral pattern changes, thereby providing solid 
experimental evidence for the intervention of the compound in the aggregation process [83]. 
The effect of plain QC was studied first to serve as reference in the evaluation of the effectiveness of 
the QC-loaded NPs. In the presence of QC, at ratios of Aβ:QC of 1:0.5 and 1:1, changes are recorded 
in the aggregation spectra of Aβ (Fig. 12A). At the 1:0.5 ratio, a composite peak gradually develops, 
which appears stabilized in solution after day 9 and does not further evolve into insoluble 
aggregates, typical of solutions of plain Aβ. At the 1:1 ratio, a gradual reduction in the intensity of 
the initial signal is observed, undergoing no further alterations after day 13. At both Aβ:QC ratios, 
the thioflavin T (ThT) fluorescence test, that detects mature amyloid fibrils, showed essentially lack 
of formation of typical fibrils (Fig. 12B). Apparently, the noticeable reduction in the intensity of the 
CD signal, noted at the 1:1 ratio, is associated with the formation of other types of macromolecular 
entities that do not behave as typical Aβ fibrils in the ThT test. QC has been shown to inhibit Aβ fibril 
formation through fluorescence spectroscopic studies and electron microscopy [84,85], however, 
this is the first time that direct interaction of QC with Aβ and inhibition of fibril formation is 
demonstrated through CD. Furthermore, the appearance of the CD spectra suggests that, under our 
conditions, inhibition of fibril formation takes place through interaction of QC with lower-order Aβ 
species early in the fibrilization process. This finding is in contrast to a literature report, proposing 
that QC binds to Aβ fibrils at the growing ends [86], in agreement however with the general notion 
that biophenols interact with Aβ monomers and oligomers of Aβ, blocking its self-assembly into 
amyloid fibrils [87]. 
 
Fig. 12. CD and ThT analysis of the QC-loaded NPs against Aβ aggregation. A) CD spectra of 50 μM of 
Aβ40 in phosphate buffer (PB 10 mM, pH 7.33), in the absence or presence of QCMMSNPs, 
QCMSNPs, and QC (1:0.5 and 1:1 ratio). Spectra were collected over a period of 27 d at 33 ◦C. 
Representative spectra from n = 3 independent experiments are presented. B) Fluorescence spectra 
of ThT (5 μМ in PB 10 mM, pН 7.33) added to Aβ (25 μМ) solutions incubated for 27 d, in the 
absence or presence of QCMMSNPs, QCMSNPs, and QC (1:0.5 and 1:1 ratio). Fluorescence was 
monitored after excitation at 440 nm. Representative spectra from n = 3 independent experiments 
are presented. 
Next, the action of QCMMSNPs on the aggregation of Aβ was examined, in order to assess their 
effectiveness as carriers of QC. As the time frame of Aβ aggregation, which proceeds for days under 
our conditions, is much larger than the time frame of QC release from QCMMSNPs, which is 
completed within 1 h under the same conditions (Fig. 11), it is presumed that QC will be available in 
solution for interaction with Aβ at the early stages of the aggregation process. As can be seen in Fig. 
12A, addition of QCMMSNPs at a Aβ:NP ratio of 1:0.5 shows initially a deepening of the negative 
peak at 198 nm relative to plain Aβ, indicative of interaction. From that point on, it appears that 
aggregation advances, and at day 9 the CD signal is already reduced to its final value. It appears that 
at the Aβ:NP 1:0.5 ratio (based on the released QC according to the in vitro release study, vide 
supra), aggregation of Aβ proceeds faster in the presence of QCMMSNPs and with no visible 
presence of β-sheet formation characterizing the aggregation spectra of Aβ. At the elevated ratio of 
Aβ:NP 1:1, the β-sheet signal is visible at day 9, with a negative maximum at 218 nm, which in the 
following days appears to be stabilized as no further evolution toward insoluble aggregates takes 
place apart from a small reduction in its intensity. It should be noted that the CD spectra of 
QCMMSNPs, in the absence of Aβ, were also obtained over a 27 day period to serve as control and 
no changes were recorded (Fig. S3, Supplementary Information). 
The ThT test (Fig. 12B), which measures the amount of typical amyloid fibrils formed, was 
subsequently performed on all CD samples [44]. As can be seen, it shows noticeable reduction in the 
amount of fibrils formed in the case of the Aβ:NP ratio of 1:0.5, which becomes even more 
significant at the Aβ:NP 1:1 ratio, in agreement with the CD data. It is evident from the data that 
QCMMSNPs are active against Аβ aggregation. However, before reaching a well-defined conclusion 
on the contribution of released QC, it was necessary to evaluate the effect of EMMSNPs on Aβ 
aggregation. Interestingly enough, EMMSNPs have an effect on the aggregation course of Aβ, even 
in the absence of QC (Fig. S4, Supplementary Information). Their presence results in changes of the 
typical appearance of the Aβ aggregation profile, denoting interaction. As can be seen (Fig. S4, 
Supplementary Information), the end result is loss of signal, indicating aggregate formation, a fact 
that was also confirmed through the ThT test, which showed formation of typical amyloid fibrils (Fig. 
S5, Supplementary Information). Therefore, in the presence of QCMMSNPs, interaction takes place 
with both the MNPs and the released QC, however, the reduction in fibril formation can only be 
ascribed to QC, based on solid evidence from CD and ThT data. 
For comparative purposes, the interaction of non-magnetized QCMSNPs synthesized and evaluated 
against oxidative stress in neurodegeneration [37] was also studied through CD. As observed in the 
case of the MNPs, QCMSNPs are definitely active against Aβ aggregation (Fig. 12A). At the lower 
Aβ:NP ratio of 1:0.5 [37], QCMSNPs stabilize β-sheet-like formation that does not proceed any 
further, whereas at the higher ratio of 1:1, composite peaks between random coil and β-sheet 
remain in solution with no further advancement. The ThT test showed great reduction in fibril 
formation at the 1:0.5 ratio and complete inhibition at the 1:1 ratio (Fig. 12B). The effect of EMSNPs 
was also evaluated and, as in the case of MNPs, it appears that there is interaction with Aβ (Figs. S4 
and S5, Supplementary Information), which however does not inhibit fibril formation. 
Comparison of our data on QCMMSNPs and QCMSNPs, clearly shows that the amount of QC present 
in solution plays a role, since in all cases, inhibition of aggregation is greater at the 1:1 ratio, where 
more QC is present. Increasing the relative concentration of QCMMSNPs relative to the Aβ (based on 
the released QC according to the in vitro release study, vide supra) in order to increase the amount 
of available QC, was not successful, as the aggregating effect of QCMMSNPs overwhelms the 
inhibitory effect of QC and rapid aggregation and fibril formation is observed, as demonstrated with 
ThT and CD studies at the Aβ:NP ratios of 1:2 and 1:3 (Figs. S5 and S6, Supplementary Information). 
Furthermore, it is clear from the data that the availability of QC in the beginning of the aggregation 
process, results in a more effective inhibition of fibril formation. At the 50 μM concentration, 
employed for the 1:1 ratio studies, plain QC results in complete inhibition of fibril formation, 
QCMSNPs (release study) [37] exhibit again complete inhibition of fibril formation, whereas 
QCMMSNPs (Section 3.12) inhibit fibril formation to a lesser extent (Fig. 12B). The fact that early 
presence of QC totally prevents fibril formation further supports our contention that interaction of 
QC takes place with lower order aggregates of Aβ. 
3.14. Rescue of primary neuronal cells from Aβ toxicity 
The capacity of the NPs, under investigation, to rescue cells from Aβ toxicity was measured through 
the MTT assay, which is widely used in neurotoxicity studies of aggregating peptides [88]. As shown 
in Fig. 13A, exposure of primary hippocampal neurons to Aβ40 (1 μM) reduces cell viability to 67% of 
untreated cells. This reduction is in accordance with values reported in the literature for Aβ40 
toxicity in primary neurons [89]. The presence of QCMMSNPs in the Aβ solution rescues cells from 
Aβ toxicity and raises viability to 70.3% for the Aβ:NP 1:0.5 ratio and 85.2% for the Aβ:NP 1:1 ratio 
(Fig. 13A), resulting in rescue effects of 4.5% and 26.9%, respectively. The rise in viability is much 
more intense in the presence of QCMSNPs, with rescue effects reaching 26.9% for the Aβ:NP 1:0.5 
ratio and 34.3% for the 1:1 ratio [37]. As expected from its known anti-aggregation properties 
[62,90], which were confirmed through CD spectroscopy, plain QC raised the viability of primary 
hippocampal neurons, resulting in rescue effects of 37.3% and 43.3% for the Aβ:QC 1:0.5 and 1:1, 
respectively. It is clear from the above data that the exerted rescue effect depends on the amount of 
QC present in solution, however, further increase in the relative amount of NPs compared to Aβ was 
not attempted, as 1 μМ of QCMSNPs and EMSNPs [37] exhibit moderate cytotoxicity even in the 
absence of Aβ (Fig. 13A). Even though direct comparisons cannot be made, this cytotoxicity is within 
the range of the cytotoxicity values reported for NPs of various compositions in primary cells [91]. 
3.15. Intracellular ROS measurements 
The effect of NPs, under evaluation, on ROS generation induced by Aβ40 in primary hippocampal 
neurons was examined and the results are summarized in Fig. 13B. Exposure of the cells to 1 μМ 
Aβ40 for 24 h resulted in a burst of ROS production as evidenced by the 10-fold increase in the 
fluorescence of the DCF dye generated from the reaction of its non-fluorescent precursor with 
peroxo radicals [92]. This increase is in accordance with literature data [93]. Co-incubation with 
QCMMSNPs at Aβ40:NP ratios of 1:0.5 and 1:1 (based on the released QC according to the in vitro 
release study, vide supra) decreases the generated DCF fluorescence by 17.1% and 28.8%, 
respectively, the reduction being even more noticeable in the case of QCMSNPs with values of 36.9% 
and 41.4% for the same ratios. Under our conditions, the presence of plain QC resulted in reduction 
of fluorescence by 45.4% for the Aβ:QC 1:0.5 ratio and 53.2% for the Aβ:QC 1:1 ratio, in agreement 
with literature data [94]. It is obvious from the data that both types of QC-loaded NPs have a great 
impact on ROS formation with the Aβ40:NP 1:1 ratio, which is associated with a higher amount of QC 
in solution, being the one most effective. Our control experiments with all nanoparticles employed 
in the study (QCMSNPs, QCMMSNPs, Fig. 13B, and the Fe3O4-PEG3k NPs, Fig. S7, Supplementary 
Information) indicate that all antioxidant action recorded in the presence of Aβ is associated with 
released QC and not the nanocarrier itself. As in the cytotoxicity studies, a higher proportion of NPs 
compared to Aβ was not attempted, as the NPs themselves induce generation of ROS to a limited 
extent (Fig. 13B). 
 
Fig. 13. Аβ-induced cell toxicity and oxidative stress studies. A) Effects of 0.5 and 1 μМ of 
QCMMSNPs, QCMSNPs, and QC on the cytotoxicity of 1 μМ Aβ40, in primary mouse hippocampal 
neurons, after 24 h of incubation at 37 ◦C. Cell viability was assessed using the MTT assay (n = 3 
independent experiments, each one performed in six replicates). B) Effect of 1 μМ of QCMMSNPs, 
QCMSNPs, and QC on Aβ40 (1 μМ) induced ROS generation in primary mouse hippocampal neurons, 
after 24 h of incubation at 37 ◦C. ROS levels were measured by DCF fluorescence assay (n = 3 
independent experiments, each one performed in six replicates). The data are presented as mean ± 
SEM, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ns (not significant) > 0.05 compared to Aβ40 (1 μM) 
treatment and #p < 0.01 and ##p < 0.01, ###p < 0.001 compared to control (untreated cells). 
4. Conclusions 
In pursuit of development of advanced NP-based drug formulations as stable, long-life and 
bioavailable nanocarriers of natural flavonoids, novel QC-loaded modified magnetic core-shell 
mesoporous silica nano-formulations were synthesized, physicochemically characterized and 
biologically evaluated in anti-amyloid and antioxidant assays. The hybrid nanocarriers showed 
exceptional stability in physiological media and exhibited enhanced solubility of the encapsulated QC 
compared to the free flavonoid, as evidenced through entrapment efficiency and loading capacity 
results, and in vitro release studies, data that imply increased bioavailability of the QC load. 
Furthermore, the generated MMSNPs preserved the superparamagnetic behavior of the employed 
surface-modified MNP core, an advantageous feature for magnetic targeting applications. 
Examination of their biological properties revealed that released QC retains its antioxidant and anti-
amyloid properties, showing that nano-encapsulation does not affect the multifaceted bioactivity of 
QC. The biological evaluation studies, based on two important properties of QC, serve as proof of 
concept on the feasibility of magnetically directed on-site release of active QC to exert its multitude 
of pharmacological activities. Collectively, the present work projects the ability of MMSNPs to 
function as efficient nanocarriers of bioactive flavonoids and sets the stage for further development 
of advanced magnetic nano-platforms for targeted therapeutic applications. 
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